FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024586523> ?p ?o ?g. }

• W2024586523 endingPage "680" @default.
• W2024586523 startingPage "673" @default.
• W2024586523 abstract "Background Combining targeted treatments for renal cell carcinoma has been suggested as a possible method to improve treatment efficacy. We aimed to assess the potential synergistic or additive effect of the combination of bevacizumab, directed against the VEGF receptor, and temsirolimus, an mTOR inhibitor, in metastatic renal cell carcinoma. Methods TORAVA was an open-label, multicentre randomised phase 2 study undertaken in 24 centres in France. Patients aged 18 years or older who had untreated metastatic renal cell carcinoma were randomly assigned (2:1:1) to receive the combination of bevacizumab (10 mg/kg every 2 weeks) and temsirolimus (25 mg weekly; group A), or one of the standard treatments: sunitinib (50 mg/day for 4 weeks followed by 2 weeks off; group B), or the combination of interferon alfa (9 mIU three times per week) and bevacizumab (10 mg/kg every 2 weeks; group C). Randomisation was done centrally and independently from other study procedures with computer-generated permuted blocks of four and eight patients stratified by participating centre and Eastern Cooperative Oncology Group performance status. The primary endpoint was progression-free survival (PFS) at 48 weeks (four follow-up CT scans), which was expected to be above 50% in group A. Analysis was by intention to treat. The study is ongoing for long-term overall survival. This study is registered with ClinicalTrials.gov, number NCT00619268. Findings Between March 3, 2008 and May 6, 2009, 171 patients were randomly assigned: 88 to the experimental group (group A), 42 to group B, and 41 to group C. PFS at 48 weeks was 29·5% (26 of 88 patients, 95% CI 20·0–39·1) in group A, 35·7% (15 of 42, 21·2–50·2) in group B, and 61·0% (25 of 41, 46·0–75·9) in group C. Median PFS was 8·2 months (95% CI 7·0–9·6) in group A, 8·2 months (5·5–11·7) in group B, and 16·8 months (6·0–26·0) in group C. 45 (51%) of 88 patients in group A stopped treatment for reasons other than progression compared with five (12%) of 42 in group B and 15 (38%) of 40 in group C. Grade 3 or worse adverse events were reported in 68 (77%) of 88 patients in group A versus 25 (60%) of 42 in group B and 28 (70%) of 40 in group C. Serious adverse events were reported in 39 (44%) of 88, 13 (31%) of 42, and 18 (45%) of 40 patients in groups A, B, and C, respectively. Interpretation The toxicity of the temsirolimus and bevacizumab combination was much higher than anticipated and limited treatment continuation over time. Clinical activity was low compared with the benefit expected from sequential use of each targeted therapy. This combination cannot be recommended for first-line treatment in patients with metastatic renal cell carcinoma. Funding French Ministry of Health and Wyeth Pharmaceuticals." @default.
• W2024586523 created "2016-06-24" @default.
• W2024586523 creator A5019588141 @default.
• W2024586523 creator A5020353650 @default.
• W2024586523 creator A5021549650 @default.
• W2024586523 creator A5026462289 @default.
• W2024586523 creator A5029182920 @default.
• W2024586523 creator A5035139653 @default.
• W2024586523 creator A5040479101 @default.
• W2024586523 creator A5049672639 @default.
• W2024586523 creator A5061604766 @default.
• W2024586523 creator A5067036952 @default.
• W2024586523 creator A5069166380 @default.
• W2024586523 creator A5072757261 @default.
• W2024586523 creator A5076354847 @default.
• W2024586523 creator A5082227510 @default.
• W2024586523 date "2011-07-01" @default.
• W2024586523 modified "2023-10-09" @default.
• W2024586523 title "Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial" @default.
• W2024586523 cites W1971211622 @default.
• W2024586523 cites W1975058097 @default.
• W2024586523 cites W1984254136 @default.
• W2024586523 cites W1988212666 @default.
• W2024586523 cites W1988826649 @default.
• W2024586523 cites W1995379903 @default.
• W2024586523 cites W1996715118 @default.
• W2024586523 cites W1999966467 @default.
• W2024586523 cites W2012063336 @default.
• W2024586523 cites W2032191175 @default.
• W2024586523 cites W2035763807 @default.
• W2024586523 cites W2054857153 @default.
• W2024586523 cites W2066604995 @default.
• W2024586523 cites W2085295027 @default.
• W2024586523 cites W2099146388 @default.
• W2024586523 cites W2100669312 @default.
• W2024586523 cites W2104540972 @default.
• W2024586523 cites W2118677643 @default.
• W2024586523 cites W2129820508 @default.
• W2024586523 cites W2130626169 @default.
• W2024586523 cites W2139248078 @default.
• W2024586523 cites W2143782771 @default.
• W2024586523 cites W2146711059 @default.
• W2024586523 cites W2149456801 @default.
• W2024586523 cites W2149721689 @default.
• W2024586523 cites W2152190103 @default.
• W2024586523 cites W2153867442 @default.
• W2024586523 cites W2162424705 @default.
• W2024586523 cites W2164638888 @default.
• W2024586523 cites W2166788033 @default.
• W2024586523 cites W2169853174 @default.
• W2024586523 cites W2170494050 @default.
• W2024586523 cites W2464502417 @default.
• W2024586523 cites W4293241248 @default.
• W2024586523 doi "https://doi.org/10.1016/s1470-2045(11)70124-3" @default.
• W2024586523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21664867" @default.
• W2024586523 hasPublicationYear "2011" @default.
• W2024586523 type Work @default.
• W2024586523 sameAs 2024586523 @default.
• W2024586523 citedByCount "219" @default.
• W2024586523 countsByYear W20245865232012 @default.
• W2024586523 countsByYear W20245865232013 @default.
• W2024586523 countsByYear W20245865232014 @default.
• W2024586523 countsByYear W20245865232015 @default.
• W2024586523 countsByYear W20245865232016 @default.
• W2024586523 countsByYear W20245865232017 @default.
• W2024586523 countsByYear W20245865232018 @default.
• W2024586523 countsByYear W20245865232019 @default.
• W2024586523 countsByYear W20245865232020 @default.
• W2024586523 countsByYear W20245865232021 @default.
• W2024586523 countsByYear W20245865232022 @default.
• W2024586523 countsByYear W20245865232023 @default.
• W2024586523 crossrefType "journal-article" @default.
• W2024586523 hasAuthorship W2024586523A5019588141 @default.
• W2024586523 hasAuthorship W2024586523A5020353650 @default.
• W2024586523 hasAuthorship W2024586523A5021549650 @default.
• W2024586523 hasAuthorship W2024586523A5026462289 @default.
• W2024586523 hasAuthorship W2024586523A5029182920 @default.
• W2024586523 hasAuthorship W2024586523A5035139653 @default.
• W2024586523 hasAuthorship W2024586523A5040479101 @default.
• W2024586523 hasAuthorship W2024586523A5049672639 @default.
• W2024586523 hasAuthorship W2024586523A5061604766 @default.
• W2024586523 hasAuthorship W2024586523A5067036952 @default.
• W2024586523 hasAuthorship W2024586523A5069166380 @default.
• W2024586523 hasAuthorship W2024586523A5072757261 @default.
• W2024586523 hasAuthorship W2024586523A5076354847 @default.
• W2024586523 hasAuthorship W2024586523A5082227510 @default.
• W2024586523 hasConcept C126322002 @default.
• W2024586523 hasConcept C126894567 @default.
• W2024586523 hasConcept C141071460 @default.
• W2024586523 hasConcept C143998085 @default.
• W2024586523 hasConcept C168563851 @default.
• W2024586523 hasConcept C183713625 @default.
• W2024586523 hasConcept C185592680 @default.
• W2024586523 hasConcept C190283241 @default.
• W2024586523 hasConcept C203092338 @default.
• W2024586523 hasConcept C2776694085 @default.
• W2024586523 hasConcept C2776820818 @default.
• W2024586523 hasConcept C2777472916 @default.

• next